Corient Private Wealth LLC Sells 48,322 Shares of Humana Inc. (NYSE:HUM)

Corient Private Wealth LLC lowered its holdings in Humana Inc. (NYSE:HUM) by 64.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 26,790 shares of the insurance provider’s stock after selling 48,322 shares during the quarter. Corient Private Wealth LLC’s holdings in Humana were worth $6,797,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in HUM. Natixis Advisors LLC grew its position in Humana by 36.4% during the fourth quarter. Natixis Advisors LLC now owns 131,418 shares of the insurance provider’s stock worth $33,342,000 after buying an additional 35,043 shares in the last quarter. Frank Rimerman Advisors LLC lifted its stake in Humana by 37.4% in the fourth quarter. Frank Rimerman Advisors LLC now owns 1,478 shares of the insurance provider’s stock worth $375,000 after purchasing an additional 402 shares during the last quarter. Alpine Woods Capital Investors LLC purchased a new stake in Humana during the 4th quarter valued at about $558,000. Madison Investment Advisors LLC purchased a new stake in shares of Humana during the fourth quarter valued at approximately $2,038,000. Finally, LFA Lugano Financial Advisors SA boosted its position in Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.37% of the company’s stock.

Humana Trading Down 0.3 %

NYSE HUM opened at $266.62 on Friday. The stock’s fifty day moving average price is $271.39 and its 200-day moving average price is $278.13. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a market cap of $32.18 billion, a P/E ratio of 26.80, a P/E/G ratio of 2.05 and a beta of 0.57. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46.

Humana (NYSE:HUM) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.33%. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Truist Financial lifted their price objective on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. StockNews.com downgraded shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 target price on shares of Humana in a research report on Wednesday, February 12th. JPMorgan Chase & Co. reduced their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Finally, Piper Sandler raised their price objective on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. Nineteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.